Researchers from Analysis Group , a global leader in health economics and outcomes research (HEOR), have co-developed a new framework that leverages findings from clinical trials and real-world ...

Petri Dish: a new AbbVie deal, layoffs, and CFO departures © 2025 American City Business Journals. All rights reserved. Use of and/or registration on any portion of ...

If consummated, the marriage will also give AbbVie access to Aliada's MODEL platform for delivering large-molecule drugs across the blood-brain barrier (BBB). The Boston biotech said the platform ...

Boston biotech Kojin Therapeutics is closing its doors, citing four funding challenges and a few valuable lessons learned.  ...

Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...

Although a waiver was placed on HIV/AIDS programmes in last month's U.S. foreign aid funding freeze, many concerns remained about the future of treatment programmes, the deputy executive director of ...

SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, ...